Victoria Lucía Collada Sánchez

Victoria Lucía Collada Sánchez

Auto-generated profile, based on publicly available information

Victoria Lucía Collada Sánchez

Hospital Pharmacy Department, La Paz University Hospital, Madrid, Spain

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 January 2023 in Expert Review of Hematology
Verified
Journal Article
Closed access
NBNuria Blazquez-Ramos
Nuria Blazquez-Ramos
JRJosé A. Romero-Garrido
José A. Romero-Garrido
LVLuis Gonzalez Del Valle
Luis Gonzalez Del Valle
VCVictoria L. Collada-Sanchez
Victoria L. Collada-Sanchez
MRMaría Teresa Álvarez Román
María Teresa Álvarez Román
Emerito Carlos Rodriguez-MerchanEmerito Carlos Rodriguez-Merchan
Emerito Carlos Rodriguez-Merchan
Guidelines for congenital coagulopathies recommend that patients record treatment administrations and bleeding episodes to help healthcare professionals monitor the disease.We studied over two year...

2 August 2024 in Journal of Oncology Pharmacy Practice
Verified
Journal Article
Closed access
JCJavier Álvarez Criado
Javier Álvarez Criado
PAPilar Zamora Auñon
Pilar Zamora Auñon
VMVirginia Martínez Marín
Virginia Martínez Marín
MCMacarena Garcíatrevijano Cabetas
Macarena Garcíatrevijano Cabetas
VSVictoria Lucía Collada Sánchez
Victoria Lucía Collada Sánchez
AAAlicia Herrero Ambrosio
Alicia Herrero Ambrosio
Objectives: The objective of this investigation was to assess the impact of concurrent proton pump inhibitors (PPIs) on progression-free survival (PFS) in patients with hormone receptor-positive and HER2-negative metastatic breast cancer (mBC) who received palbociclib as first-line or successives therapy. Materials and Methods: A retrospective observational study was conducted, enrolling patients diagnosed with estrogen receptor-positive, human epidermal growth factor receptor 2-negative mBC, and eligible for palbociclib treatment. Patients were categorized as “concurrent PPIs” if they received PPIs for at least two-thirds of the palbociclib therapy duration, and as “no concurrent PPIs” if they did not receive PPIs during the course of palbociclib treatment. Results: A total of 165 patients were included in the study. Among first-line patients treated with palbociclib, those using concurrent PPIs exhibited a PFS of 8.88 months, while patients using palbociclib without concurrent PPIs had a PFS of 67.81 months (p < 0.0001). In second-line or subsequent treatments, patients on palbociclib with concurrent PPIs had a PFS of 7.46 months, whereas those using palbociclib without concurrent PPIs had a PFS of 17.29 months (p = 0.122). Conclusion: This study demonstrates that the concurrent use of PPIs in mBC patients receiving palbociclib negatively affects PFS, particularly in the first-line setting. Nevertheless, further investigation is warranted to explore the impact of PPIs on cycle-dependent kinase 4/6 inhibitors.